Heat Biologics (HTBX) Stock Price Down 11.9%
Heat Biologics Inc (NASDAQ:HTBX) was down 11.9% during mid-day trading on Thursday . The stock traded as low as $0.72 and last traded at $0.74. Approximately 1,107,625 shares changed hands during trading, an increase of 118% from the average daily volume of 507,289 shares. The stock had previously closed at $0.84.
Several equities research analysts have recently issued reports on HTBX shares. ValuEngine lowered shares of Heat Biologics from a “hold” rating to a “sell” rating in a research note on Wednesday, May 1st. Alliance Global Partners set a $6.00 target price on shares of Heat Biologics and gave the stock a “buy” rating in a research note on Friday, May 17th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $7.67.
The company has a quick ratio of 5.70, a current ratio of 5.70 and a debt-to-equity ratio of 0.01.
WARNING: “Heat Biologics (HTBX) Stock Price Down 11.9%” was first published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://www.watchlistnews.com/heat-biologics-htbx-stock-price-down-11-9/3022171.html.
Heat Biologics Company Profile (NASDAQ:HTBX)
Heat Biologics, Inc, a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness.
Recommended Story: What is a trade deficit?
Receive News & Ratings for Heat Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics and related companies with MarketBeat.com's FREE daily email newsletter.